Zinc oxide nanoparticles show antidiabetic activity in streptozotocin- induced Type 1 and 2 diabetic rats

Nanomedicine

Volumn 9, Issue 1, 2014, Pages 89-104

  Umrani, Rinku D ^a   Paknikar, Kishore M ^a  

^a AGHARKAR RESEARCH INSTITUTE   (India)

Author keywords

diabetes; nanoparticle; rat; streptozotocin; zinc

Indexed keywords

ANTIDIABETIC AGENT; FATTY ACID; GLUCOSE; INSULIN; NANOPARTICLE; STREPTOZOCIN; SUPEROXIDE DISMUTASE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; ZINC OXIDE NANOPARTICLE;

ACUTE TOXICITY; ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDIABETIC ACTIVITY; ARTICLE; BLOOD TOXICITY; CYTOTOXICITY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG MECHANISM; ENZYME ACTIVITY; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; HEMOLYSIS; INSULIN BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; INSULINOMA; LIVER; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PANCREAS; PRIORITY JOURNAL; RAT; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; TOXICITY TESTING;

ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; LIVER; NANOPARTICLES; RATS; RATS, WISTAR; ZINC OXIDE;

EID: 84880145632     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.12.205     Document Type: Article

References (41)

1. Lin Y, Sun Z. Current views on Type 2 diabetes. J. Endocrinol. 204(1), 1-11 (2010).
2. Thompson KH, Lichter J, LeBel C, Scaife MC, McNeill JH, Orvig C. Vanadium treatment of Type 2 diabetes: a view to the future. J. Inorg. Biochem. 103(4), 554-558 (2009).
3. Wang ZQ, Cefalu WT. Current concepts about chromium supplementation in Type 2 diabetes and insulin resistance. Curr. Diab. Rep. 10(2), 145-151 (2010).
4. Wells IC. Evidence that the etiology of the syndrome containing Type 2 diabetes mellitus results from abnormal magnesium metabolism. Can. J. Physiol. Pharmacol. 86(1-2), 16-24 (2008).
5. Vasudevan H, McNeill JH. Chronic cobalt treatment decreases hyperglycemia in streptozotocin diabetic rats. Biometals 20(2), 129-134 (2007).
6. Chausmer AB. Zinc, insulin and diabetes. J. Am. Coll. Nutr. 17(2), 109-115 (1998).
7. Haase H, Overbeck S, Rink L. Zinc supplementation for the treatment or prevention of disease: current status and future perspectives. Exp. Gerontol. 43(5), 394-408 (2008).
8. Jansen J, Karges W, Rink L. Zinc and diabetes-clinical links and molecular mechanisms. J. Nutr. Biochem. 20(6), 399-417 (2009).
9. Ueda E, Yoshikawa Y, Sakurai H, Kojima Y, Kajiwara NM. In vitro alpha-glucosidase inhibitory effect of Zn (II) complex with 6-methyl-2- picolinmethylamide. Chem. Pharm. Bull. 53(4), 451-452 (2005).
10. Ishihara H, Maechler P, Gjinovci A, Herrera PL, Wollheim CB. Islet beta-cell secretion determines glucagon release from neighboring alpha-cells. Nat. Cell. Biol. 5(4), 330-335 (2003).
11. Egefjord L, Petersen AB, Bak AM, Rungby J. Zinc, alpha cells and glucagon secretion. Curr. Diabetes Rev. 6(1), 52-57 (2010).
12. Sun Q, VanDam RM, Willett WC, Hu FB. Prospective study of zinc intake and risk of Type 2 diabetes in women. Diabetes Care 32(4), 629-634 (2009).
13. Smidt K, Jessen N, Petersen AB et al. SLC30A3 responds to glucose-and zinc variations in b-cells and is critical for insulin production and in vivo glucose-metabolism during b-cell stress. PLoS One 4(5), e5684 (2009).
14. Rungby J. Zinc, zinc transporters and diabetes. Diabetologia 53(8), 1549-1551 (2010).
15. Wijesekara N, Dai FF, Hardy AB et al. Beta cell-specific ZnT8 deletion in mice causes marked defects in insulin processing, crystallization and secretion. Diabetologia 53(8), 1656-1658 (2010).
16. Hiromura M, Sakurai H. Action mechanism of metallo-allixin complexes as anti-diabetic agents. Pure Appl. Chem. 80(12), 2727-2733 (2008).
17. Wilson M, Hogstrand C, Maret W. Picomolar concentrations of free zinc(II) ions regulate receptor protein-tyrosine phosphatase b activity. J. Biol. Chem. 287(12), 9322-9326 (2012).
18. Meyer JA, Spence DM. A perspective on the role of metals in diabetes: past findings and possible future directions. Metallomics 1, 32-41 (2009).
19. Ukperoro JU, Offiah N, Idris T, Awogoke D. Antioxidant effect of zinc, selenium and their combination on the liver and kidney of alloxan-induced diabetes in rats. Med. J. Nutr. Metab. 3(1), 25-30 (2010).
20. Bolkent S, Yanardag R, Bolkent S, Mutlu O. The influence of zinc supplementation on the pancreas of streptozotocin diabetic rats. Dig. Dis. Sci. 54(12), 2583-2587 (2009).
21. Yoshikawa Y, Adachi Y, Sakurai H. A new type of orally active anti-diabetic Zn (II)-dithiocarbamate complex. Life Sci. 80(8), 759-766 (2007).
22. Karmaker S, Saha TK, Yoshikawa Y, Sakurai H. A zinc(II)/poly(g-glutamic acid) complex as an oral therapeutic for the treatment of Type-2 diabetic KKAy mice. Macromol. Biosci. 9(3), 279-286 (2009).
23. Rodrigues B, Poucheret P, Battel ML, McNeill JH. Streptozotocin induced diabetes: induction, mechanism(s) and dose dependency. In: Experimental Models of Diabetes. McNeill JH (Ed.). CRC Press LLC, NY, USA, 3-17 (1999).
24. Schaffer SW, Mozaffari M. The neonatal STZ model of diabetes. In: Experimental Models of Diabetes. McNeill JH (Ed.). CRC Press LLC, NY, USA, 231-255 (1999).
25. Richards-Williams C, Contreras JL, Berecek KH, Schwiebert EM. Extracellular ATP and zinc are co-secreted with insulin and activate multiple P2X purinergic receptor channels expressed by islet beta-cells to potentiate insulin secretion. Purinergic Signal. 4(4), 393-405 (2008).
26. Cortese MM, Suschek CV, Wetzel W, Kroncke KD, Kolb-Bachofen V. Zinc protects endothelial cells from hydrogen peroxide via Nrf2-dependent stimulation of glutathione biosynthesis. Free Radic. Biol. Med. 44(12), 2002-2012 (2008).
27. Dawei A, Zhisheng W, Anguo Z. Protective effects of nano-ZnO on the primary culture mice intestinal epithelial cells in vitro against oxidative injury. J. Anim. Vet. Adv. 8(10), 1964-1967 (2009).
28. Rungby J, Flyvbjerg A, Andersen HB, Nyborg K. Lipid peroxidation in early experimental diabetes in rats: effects of diabetes and insulin. Acta Endocrinol. 126(4), 378-380 (1992).
29. Quesada I, Tuduri E, Ripoll C, Nadal A. Physiology of the pancreatic alpha-cell and glucagon secretion: role in glucose homeostasis and diabetes. J. Endocrinol. 199(1), 5-19 (2008).
30. Nakayama A, Hiromura M, Adachi Y, Sakurai H. Molecular mechanism of anti-diabetic zinc-allixin complexes: regulations of glucose utilization and lipid metabolism. J. Biol. Inorg. Chem. 13(5), 675-684 (2008).
31. Yoshikawa Y, Adachi Y, Yasui H, Hattori M, Sakurai H. Oral administration of bis(aspirinato)zinc(II) complex ameliorates hyperglycemia and metabolic syndrome-like disorders in spontaneously diabetic KK-Ay mice: structure-activity relationship on zinc-salicylate complexes. Chem. Pharm. Bull. 59(8), 972-977 (2011).
32. Li SD, Huang L. Pharmacokinetics and biodistribution of nanoparticles. Mol. Pharm. 5(4), 496-504 (2008).
33. Nel AE, Madler L, Velegol D et al. Understanding biophysicochemical interactions at the nano-bio interface. Nat. Mater. 8(7), 543-557 (2009).
34. Ishihara K, Yamanami K, Takano M et al. Zinc bioavailability is improved by the micronized dispersion of zinc oxide with the addition of l-histidine in zinc-deficient rats. J. Nutr. Sci. Vitaminol. 54(1), 54-60 (2008).
35. Hilty FM, Arnold M, Hilbe M et al. Iron from nanocompounds containing iron and zinc is highly bioavailable in rats without tissue accumulation. Nat. Nanotechnol. 5(5), 374-380 (2010).
36. Franklin NM, Rogers NJ, Apte SC, Batley GE, Gadd GE, Casey PS. Comparative toxicity of nanoparticulate ZnO, bulk ZnO, and ZnCl2 to a freshwater microalga (Pseudokirchneriella subcapitata): the importance of particle solubility. Environ. Sci. Technol. 41(24), 8484-8490 (2007).
37. Lichten LA, Cousins RJ. Mammalian zinc transporters: nutritional and physiologic regulation. Annu. Rev. Nutr. 29, 153-176 (2009).
38. Xia T, Kovochich M, Liong M et al. Comparison of the mechanism of toxicity of zinc oxide and cerium oxide nanoparticles based on dissolution and oxidative stress properties. ACS Nano 2(10), 2121-2134 (2008).
39. Stern ST, McNeil SE. Nanotechnology safety concerns revisited. Toxicol. Sci. 101(1), 4-21 (2008).
40. Mocchegiani E, Giacconi R, Malavolta M. Zinc signalling and subcellular distribution: emerging targets in Type 2 diabetes. Trends Mol. Med. 14(10), 419-428 (2008).
41. Wang B, Feng W, Wang M et al. Acute toxicological impact of nano-and submicro-scaled zinc oxide powder on healthy adult mice. J. Nanopart. Res. 10(2), 263-276 (2008).